Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who have a history of cough as sole or main symptom lasting more than 3 weeks.~2. Patients whose chest x-ray outcome was normal or without any active focus.~3. Patients who were diagnosed with the result of sputum eosinophil percentage (Eos%) over 2.5%, and the negative result in bronchial provocation test by methacholine inhalation challenge.~4. Patients who was aged from 18 years old (≥ 18 years old ) to 75 years old (≤ 75 years old).~Exclusion Criteria:~1. Patients who is a smoker or ex-smoker and has smoked within the previous year or has a cumulative smoking history \>10 pack-years or equivalence.~2. Patients with concomitance of GERC (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, ACEI induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction.~3. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study.~4. Subjects who are known or suspected to be hypersensitive to any component of the study medication or relief medications.~5. Subjects who have received any therapy in the previous 4 weeks, e.g.corticosteroids ,antihistamines, leukotriene receptor antagonist in previous 4 weeks~6. Subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia.~7. Subjects who demonstrate significant abnormality on biochemistry, hematology, ECG.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled budesonide for 4 weeks (Type: ACTIVE_COMPARATOR): inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
- Inhaled budesonide for 8 weeks (Type: ACTIVE_COMPARATOR): inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
- Inhaled budesonide for 16 weeks (Type: ACTIVE_COMPARATOR): inhaled Budesonide 100µg , 2puff Q12h for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).